Atomo Diagnostics Ltd. (AU:AT1)
ASX:AT1
Top Page
Atomo Diagnostics Ltd.
(Sydney:AT1)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.04
▼(-2.50% Downside)
Action:ReiteratedDate:03/26/26
The score is primarily held back by weak financial performance, including declining revenue, large ongoing losses, and negative operating/free cash flow. Technicals provide partial support as the price is above longer-term moving averages with mildly positive momentum, but valuation remains constrained by losses (negative P/E) and no provided dividend yield.
Positive Factors
Proprietary integrated RDT platform
Atomo’s proprietary integrated device bundles lancet, collection and delivery for lateral-flow tests, lowering partner integration costs and safety friction. This structural product advantage supports recurring B2B per-unit sales and long-term adoption in infectious disease programs.
Negative Factors
Declining revenue
Sustained revenue contraction undermines scale economics and partner confidence, delaying fixed-cost absorption required for sustainable profitability. Continued top-line shrinkage reduces negotiating power with customers and suppliers and slows the pathway to positive operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary integrated RDT platform
Atomo’s proprietary integrated device bundles lancet, collection and delivery for lateral-flow tests, lowering partner integration costs and safety friction. This structural product advantage supports recurring B2B per-unit sales and long-term adoption in infectious disease programs.
Read all positive factors
Atomo Diagnostics Ltd. (AT1) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$32.41M
Dividend YieldN/A
Average Volume (3M)1.80M
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue Growth-7.20%
EPS Growth28.70%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding810,175,300
10 Day Avg. Volume984,499
30 Day Avg. Volume1,797,539
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.30
Price to Sales (P/S)2.39
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Company Description
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is head...
How the Company Makes Money
Atomo Diagnostics makes money primarily by selling its integrated RDT device products (and related device components) to third parties that use them in rapid tests and testing programs. The company’s revenue model is business-to-business, where At...
Atomo Diagnostics Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.92M | 3.79M | 4.09M | 2.54M | 12.34M | 6.72M |
| Gross Profit | -388.74K | 1.79M | 1.44M | -6.08M | -1.85M | -1.71M |
| EBITDA | -4.33M | -4.69M | -6.12M | -9.00M | -4.72M | -4.70M |
| Net Income | -3.98M | -4.97M | -6.85M | -9.96M | -5.71M | -6.02M |
Balance Sheet | ||||||
| Total Assets | 9.48M | 9.28M | 11.38M | 16.47M | 26.62M | 32.24M |
| Cash, Cash Equivalents and Short-Term Investments | 3.51M | 3.22M | 3.69M | 6.47M | 12.97M | 17.95M |
| Total Debt | 754.39K | 185.10K | 84.67K | 254.88K | 340.81K | 67.59K |
| Total Liabilities | 2.84M | 2.30M | 1.29M | 1.68M | 1.81M | 2.15M |
| Stockholders Equity | 6.64M | 6.98M | 10.08M | 14.79M | 24.81M | 30.09M |
Cash Flow | ||||||
| Free Cash Flow | -2.23M | -1.99M | -4.70M | -6.25M | -5.11M | -10.12M |
| Operating Cash Flow | -2.19M | -1.96M | -4.69M | -5.85M | -2.81M | -4.23M |
| Investing Cash Flow | -38.88K | -33.89K | -16.08K | -401.28K | -2.31M | -5.90M |
| Financing Cash Flow | 2.75M | 1.46M | 1.87M | -170.75K | 17.61K | 997.37K |
Atomo Diagnostics Ltd. Technical Analysis
Neutral
0.04
Price Trends
0.04
Negative
0.04
Positive
0.03
Positive
Market Momentum
<0.01
Positive
56.32
Neutral
88.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AT1, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.32 is Neutral, neither overbought nor oversold. The STOCH value of 88.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:AT1.
Atomo Diagnostics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$51.35M | -9.32 | -417.72% | ― | -34.06% | 75.47% | |
48 Neutral | AU$23.07M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
47 Neutral | AU$32.41M | -4.09 | -58.40% | ― | -7.20% | 28.70% | |
43 Neutral | AU$3.12M | -0.88 | -358.43% | ― | -30.80% | -38.95% | |
41 Neutral | AU$10.75M | -0.50 | 459.94% | ― | -2.82% | 32.47% |
* Healthcare Sector Average
AU:AT1
Atomo Diagnostics Ltd.
0.04
0.02
100.00%
AU:UCM
Uscom Limited
0.01
-0.02
-60.00%
AU:HMD
HeraMED Ltd.
0.05
0.03
142.11%
AU:ADR
Adherium Ltd.
0.01
0.00
0.00%
AU:CBL
Control Bionics Ltd.
0.06
0.01
27.27%
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics Halts Trading Ahead of Key FDA Decision on FebriDx
Mar 26, 2026
Atomo Diagnostics has requested a trading halt on its ASX-listed securities pending an announcement on the U.S. Food and Drug Administration’s response to the CLIA waiver application for the FebriDx® test submitted by Lumos Diagnostics....
Atomo Diagnostics Denies Undisclosed News Behind Share Price Move
Mar 25, 2026
Atomo Diagnostics has told the ASX it is not aware of any undisclosed price-sensitive information that would explain a recent rise in its share price and trading volumes. The company confirmed it remains in full compliance with ASX continuous disc...
Atomo Diagnostics Targets Growth in Decentralized Rapid Testing Market
Feb 26, 2026
Atomo Diagnostics is sharpening its focus on the fast-growing point-of-care testing market, supplying rapid diagnostic products for professional and self-test use, particularly in sexual and female health, where demand for convenient and accurate ...
Atomo Diagnostics Narrows Half-Year Loss as Revenue Edges Higher
Feb 26, 2026
Atomo Diagnostics reported a modest 6% rise in revenues from ordinary activities to AUD2.18 million for the half year to 31 December 2025, while significantly narrowing its loss. The loss from ordinary activities after tax fell 36% to AUD1.76 mill...
Atomo Wins A$630,000 Order for Government-Backed HIV Self-Testing Program
Feb 5, 2026
Atomo Diagnostics has secured a material purchase order worth approximately A$630,000 from the National Association of People with HIV Australia to supply HIV self-tests for the national free-to-user HIV self-testing mail-out program. The governme...
Atomo Wins Second Major Global Fund–Backed Order for HIV Self-Tests
Jan 30, 2026
Atomo Diagnostics has secured a A$416,000 purchase order for its HIV self-tests, to be supplied under the Mylan brand to an African country with funding from the Global Fund, a level of revenue the company deems material. This marks the second Glo...
Atomo Diagnostics Sets Date for Q2 FY26 Results and Investor Webinar
Jan 22, 2026
Atomo Diagnostics has scheduled the release of its Q2 FY26 financial results for Wednesday, 28 January 2026, and will host an investor and analyst webinar briefing on the same day at 2:00 pm AEDT, led by Managing Director and CEO John Kelly. The c...
Atomo Diagnostics Wins Exclusive Global Licence for Rapid Liver Function Test on Pascal Platform
Jan 19, 2026
Atomo Diagnostics has secured an exclusive global licence from the Burnet Diagnostics Initiative for a novel liver function test that detects liver injury via alanine aminotransferase (ALT) using Atomo’s Pascal point-of-care cassette. The te...
Atomo Wins $502,000 HIV Self-Test Order Backed by Global Fund
Jan 14, 2026
Atomo Diagnostics Limited has secured a material purchase order worth $502,000 to supply its HIV self-test kits, manufactured under the Mylan brand, to an African country with funding from the Global Fund, with delivery planned for March. The deal...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.